Get started
Author

Giorgio Priolo

Observed names: G Priolo, G. Priolo
ORCID: 0009-0007-9928-1074
Observed ORCID: 0009-0007-9928-1074
OpenAlex ID: A5102753506
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
2012 · Patrizia Pregno, Annalisa Chiappella, et al. · Blood · 236
Production of Cytokines in Hemodialysis
2008 · C. Tetta, G. Camussi, et al. · Blood Purification · 46
Clinical relevance of hemochromatosis-related HFE C282Y/H63D gene mutations in patients on chronic dialysis
2002 · C. Canavese, D. Bergamo, et al. · Clinical Nephrology · 16
Long‐term outcome of peripheral T‐cell lymphomas: Ten‐year follow‐up of the International Prospective T‐cell Project
2024 · Monica Civallero, Joseph G. Schroers‐Martin, et al. · British Journal of Haematology · 14
PDF
Validation of National Early Warning Score and Quick Sequential ( sepsis‐related ) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy
2023 · Chiara Frairia, Barbara Nicolino, et al. · European Journal Of Haematology · 13
PDF
Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.
2009 · Patrizia Pregno, Annalisa Chiappella, et al. · Blood · 12
A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project
2018 · M. Levis, V. De Luca, et al. · International Journal of Radiation Oncology*Biology*Physics · 4
Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy
2010 · Annalisa Chiappella, Benedetta Puccini, et al. · Blood · 4
The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy.
2010 · Umberto Vitolo, Annalisa Chiappella, et al. · Blood · 4
Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.
2009 · Annalisa Chiappella, Benedetta Puccini, et al. · Blood · 4
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2022 · Giovanni Marconi, Alfonso Piciocchi, et al. · Blood · 3
Long term outcome of Peripheral T Cell Lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project Network
2023 · M. Civallero, R. Advani, et al. · Hematological Oncology · 1
PDF
Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study
2026 · Gabriele Roccuzzo, Paolo Fava, et al. · British Journal of Dermatology
Real-world effectiveness and safety of mogamulizumab in mycosis fungoides and Sézary syndrome: A multicenter observational study by the Italian Lymphoma Foundation (FIL)
2025 · Gabriele Roccuzzo, Paolo Fava, et al. · European Journal of Cancer
Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2024 · Paola Minetto, Fabio Guolo, et al. · Blood
Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML
2023 · Paola Minetto, Fabio Guolo, et al. · Blood
PDF
P553: Preliminary Results of Mrd Analysis of Aml1718, a Phase 2 Open-label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (v-flai) in the Induction Therapy of Non Low-risk Aml
2023 · Paola Minetto, Fabio Guolo, et al. · HemaSphere
KL-6 as Idiopathic Pulmonary Fibrosis (IPF) Biomarker: A Retrospective Cohort Study in 92 IPF Patients and 120 Healthy Controls
2019 · C. Albera, A. Cornio, et al. · American Journal of Respiratory and Critical Care Medicine
The Role of Mantle Cell International Prognostic Index (mipi) as Survival Predictor in Mantle Cell Lymphoma (mcl) Patients Treated With Rituximab and Chemotherapy
2010 · Annalisa Chiappella, Benedetta Puccini, et al. · Padua Research Archive (University of Padova)
Contents, Vol. 8, 1990
2008 · R. Bambauer, J. Walther, et al. · Blood Purification
PDF
Subject Index, Vol. 8, 1990
2008 · R. Bambauer, J. Walther, et al. · Blood Purification
Announcement
2008 · R. Bambauer, J. Walther, et al. · Blood Purification
PDF
Author Index, Vol. 8, 1990
2008 · R. Bambauer, J. Walther, et al. · Blood Purification
PDF
CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
1990 · G Priolo, F Pecchio, et al. · PubMed
Works count: 24
Citation count: 357
H-index: 6
I10-index: 6
Year
Topic
Type